Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate

Pharmacogenetics and Genomics

Volumn 22, Issue 10, 2012, Pages 750-757

  Frazier Wood, Alexis C ^a,b   Aslibekyan, Stella ^a   Borecki, Ingrid B ^c   Hopkins, Paul N ^d   Lai, Chao Qiang ^e   Ordovas, Jose M ^e,g,h   Straka, Robert J ^f   Tiwari, Hemant K ^b   Arnett, Donna K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b School of Public Health   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e TUFTS UNIVERSITY   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^h IMDEA FOOD INSTITUTE   (Spain)

Author keywords

AHCYL2; CD36; fenofibrate; inflammation; insulin resistance; insulin signaling; lipoprotein diameter; methylation; PPARc; subclass

Indexed keywords

CD36 ANTIGEN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; S ADENOSYLHOMOCYSTEINE HYDROLASE LIKE 2 ISOFORM; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CAUCASIAN; DIET RESTRICTION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84866326217     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328357f6af     Document Type: Article

References (49)

1. Petersen AK, Stark K, Musameh MD, Nelson CP, Römisch-Margl W, Kremer W, et al. Genetic associations with lipoprotein subfractions provide information on their biological nature. Hum Mol Genet 2012; 21:1433-1443.
2. Lemieux I, Laperriè re L, Dzavik V, Tremblay G, Bourgeois J, Després JP, et al. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 2002; 162:363-371. (Pubitemid 34457942)
3. Dreon DM, Fernstrom HA,Williams PT, Tremblay G, Bourgeois J, Després JP. Reduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns. Am J Clin Nutr 2000; 71:1611-1616. (Pubitemid 30395912)
4. Williams PT, Krauss RM, Vranizan KM, Albers JJ, Wood PD. Effects of weight-loss by exercise and by diet on apolipoproteins A-I and A-II and the particle-size distribution of high-density lipoproteins in men. Metabolism 1992; 41:441-449.
5. Hulthe J, Bokemark L,Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000; 20:2140-2147.
6. Gray RS, Robbins DC, Wang W, Yeh JL, Fabsitz RR, Cowan LD, et al. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol 1997; 17:2713-2720. (Pubitemid 28016013)
7. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007; 192:211-217. (Pubitemid 46602300)
8. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52:453-462. (Pubitemid 36173203)
9. Wood AC, Glasser S, Garvey WT, Kabagambe EK, Borecki IB, Tiwari HK, et al. Lipoprotein lipase S447X variant associated with VLDL, LDL and HDL diameter clustering in the metabolic syndrome. Lipids Health Dis 2011; 10:143.
10. Sebestjen M, Keber I, Zegura B, Simcic S, Bozic M, Fressart MM, Stegnar M. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 2004; 92:1129-1135. (Pubitemid 39545539)
11. Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity 2009; 17:504-509.
12. Rosenson RS, Huskin AL, Wolff DA, Helenowski IB, Rademaker AW. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis 2008; 198:381-388.
13. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002; 112:275-280. (Pubitemid 34219440)
14. Okopien B, Krysiak R, Kowalski J, van der Laarse A, Smelt AH. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004; 176:327-335. (Pubitemid 39369523)
15. Knopp RH,Walden CE,Warnick GR, Albers JJ, Ginsberg J, McGinnis BM. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E. Am J Med 1987; 83:75-84.
16. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905-910.
17. Feher MD, Caslake M, Foxton J, Cox A, Packard CJ. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999; 15:395-399. (Pubitemid 30066226)
18. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193: 428-437. (Pubitemid 47058108)
19. Vakkilainen J, Steiner G, Ansquer J-C, Perttunen-Nio H, Taskinen MR. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care 2002; 25:627-628.
20. Bouly M, Masson D, Gross B, Perttunen-Nio H, Taskinen MR. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem 2001; 276:25841-25847.
21. Keating GM, Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002; 62:1909-1944.
22. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108:2317-2322. (Pubitemid 37413536)
23. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86:943-949.
24. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J 2008; 84: 590-598.
25. Pankow JS, Province MA, Hunt SC, Arnett DK. Regarding 'testing for population subdivision and association in four case-control studies'. Am J Hum Genet 2002; 71:1478-1480. (Pubitemid 36015903)
26. Frazier-Wood AC, Ordovas JM, Straka RJ, Hixson JE, Borecki IB, Tiwari HK, Arnett DK. The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. Pharmacogenomics J 2012 [Epub ahead of print].
27. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992; 38:1632-1638.
28. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006; 26: 847-870. (Pubitemid 44716510)
29. Irvin MR, Kabagambe EK, Tiwari HK, Parnell LD, Straka RJ, Tsai M, et al. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ Cardiovasc Genet 2010; 3: 462-467.
30. Korn JM, Kuruvilla FG, McCarroll SA,Wysoker A, Nemesh J, Cawley S, et al. Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet 2008; 40: 1253-1260.
31. Li Y,Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34:816-834.
32. Li Y, Willer CJ, Sanna S, Abecasis GR. Genotype imputation. Annu Rev Genomics Hum Genet 2009; 10:387-406.
33. Atkinson B, Thereau T. Kinship: mixed-effects Cox models, sparse matrices, and modeling data from large pedigrees. R package version; 1(1.0-17). Available at: http://www.crantastic.org/packages/kinship; 2007.
34. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26:2336-2337.
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
36. Medina I, Montaner D, Bonifaci N, Pujana MA, Carbonell J, Tarraga J, et al. Gene set-based analysis of polymorphisms: finding pathways or biological processes associated to traits in genome-wide association studies. Nucleic Acids Res 2009; 37:W340-W344.
37. Al-Shahrour F, Arbiza L, Dopazo H, Huerta-Cepas J, Mínguez P, Montaner D, Dopazo J. From genes to functional classes in the study of biological systems. BMC Bioinformatics 2007; 8:114.
38. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25:25-29. (Pubitemid 30257031)
39. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-713.
40. Chiang PK, Gordon RK, Tal J, Zeng GC. S-adenosylmethionine and methylation. FASEB J 1996; 10:471-480. (Pubitemid 26120322)
41. Sinclair KD, Allegrucci C, Singh R, Gardner DS, Sebastian S, Bispham J, et al. DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. Proc Natl Acad Sci USA 2007; 104:19351-19356.
42. Kerins DM, Koury MJ, Capdevila A, Rana S, Wagner C. Plasma Sadenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 2001; 74:723-729. (Pubitemid 33101791)
43. Calvo D, Gomez-Coronado D, Suarez Y, Lasunció n MA, Vega MA. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res 1998; 39:777-788. (Pubitemid 28163280)
44. Febbraio MA. Null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999; 274:19055-19062.
45. Oberkofler H, Pfeifenberger A, Soyal S, Felder T, Hahne P, Miller K, et al. Aberrant hepatic TRIB3 gene expression in insulin-resistant obese humans. Diabetologia 2010; 53:1971-1975.
46. Hoeks J, Hesselink MKC, Russell AP, Mensink M, Saris WH, Mensink RP, Schrauwen P. Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: acute effect of fatty acids. Diabetologia 2006; 49:2419-2426. (Pubitemid 44359104)
47. Park KS, Shin HD, Park BL, Cheong HS, Cho YM, Lee HK, et al. Putative association of peroxisome proliferator-activated receptor gamma coactivator 1beta (PPARGC1B) polymorphism with type 2 diabetes mellitus. Diabet Med 2006; 23:635-642. (Pubitemid 43830064)
48. Sun L, Yang Z, Jin F, Zhu XQ, Qu YC, Shi XH, Wang L. The Gly482Ser variant of the PPARGC1 gene is associated with type 2 diabetes mellitus in northern Chinese, especially men. Diabet Med 2006; 23:1085-1092. (Pubitemid 44401137)
49. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, et al. Fortythree loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet 2009; 5:e1000730.